152 related articles for article (PubMed ID: 34990901)
1. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution.
Masterson WM; Brown AM; Al Ameri MA; Patel AB
Cancer Treat Res Commun; 2022; 30():100506. PubMed ID: 34990901
[TBL] [Abstract][Full Text] [Related]
2. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses.
Le TK; Kaul S; Cappelli LC; Naidoo J; Semenov YR; Kwatra SG
J Dermatolog Treat; 2022 May; 33(3):1691-1695. PubMed ID: 33656965
[TBL] [Abstract][Full Text] [Related]
4. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
Tetzlaff MT; Tang S; Duke T; Grabell DA; Cabanillas ME; Zuo Z; Yao JC; Nagarajan P; Aung PP; Torres-Cabala CA; Duvic M; Prieto VG; Huen A; Curry JL
J Cutan Pathol; 2019 Nov; 46(11):872-877. PubMed ID: 31254410
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
6. Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.
Pospischil I; Hoetzenecker W
J Dtsch Dermatol Ges; 2021 Nov; 19(11):1621-1643. PubMed ID: 34811916
[TBL] [Abstract][Full Text] [Related]
7. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes.
Hashimoto H; Ito T; Ichiki T; Yamada Y; Oda Y; Furue M
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33673164
[TBL] [Abstract][Full Text] [Related]
8. Steroid-Refractory Lichenoid Eruption Associated with Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
Kou L; Agarwal S; Miceli A; Kolb L; Krishnamurthy K; Schmieder S
HCA Healthc J Med; 2021; 2(6):397-400. PubMed ID: 37427397
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.
L'Orphelin JM; Cassecuel J; Kandolf L; Harwood CA; Tookey P; Junejo MH; Hogan S; Lebbé C; Appalla Z; Kränke TM; Pellacani G; Cerasuolo D; Dujovic B; Del Marmol V; Forschner A; Garbe C; Bataille V; Ressler JM; Sollena P; Dompmartin A; Peris K; Dreno B;
J Eur Acad Dermatol Venereol; 2023 Apr; ():. PubMed ID: 37042810
[TBL] [Abstract][Full Text] [Related]
11. Lichenoid and granulomatous dermatitis.
Magro CM; Crowson AN
Int J Dermatol; 2000 Feb; 39(2):126-33. PubMed ID: 10692062
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
Keiser MF; Patel AB; Altan M
Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
[TBL] [Abstract][Full Text] [Related]
13. Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
Fixsen E; Patel J; Selim MA; Kheterpal M
Oncologist; 2019 Mar; 24(3):e103-e105. PubMed ID: 30617087
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
Pach J; Leventhal JS
Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
[TBL] [Abstract][Full Text] [Related]
16. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Induced Psoriasiform, Spongiotic, and Lichenoid Dermatitis: A Novel Clinicopathological Pattern.
Kost Y; Mattis D; Muskat A; Amin B; McLellan B
Cureus; 2022 Aug; 14(8):e28010. PubMed ID: 36134105
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
[TBL] [Abstract][Full Text] [Related]
19. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
20. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
